TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38627238

Group type: EXPERIMENTAL
Intervention: Derazantinib monotherapy (300 mg QD in Substudy 1, 200 mg BID in Substudy 5)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Derazantinib 300 mg QD plus atezolizumab 1200 mg every 3 weeks (Substudy 2)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Derazantinib 200 mg BID plus atezolizumab 1200 mg every 3 weeks (Substudy 3)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Derazantinib 300 mg QD monotherapy (Substudy 4)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Derazantinib 300 mg QD plus atezolizumab 1200 mg every 3 weeks (Substudy 4)
Number of subjects: 49
Study: 38627266

Group type: EXPERIMENTAL
Intervention: Bright light therapy (BLT) - 10,000 lx; daily 30-min sessions for 10 weeks
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Physical exercise intervention (EI) - aerobic and muscle-strengthening activities 3 days/week for 10 weeks
Number of subjects: 207

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 207
Study: 38627366

Group type: EXPERIMENTAL
Intervention: TQ-B3525, 20 mg orally once daily in a 28-day cycle
Number of subjects: 107
Study: 38627377

Group type: EXPERIMENTAL
Intervention: Neoadjuvant PD-1 blockade plus stereotactic body radiotherapy (SBRT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Adjuvant tislelizumab
Number of subjects: 20
Study: 38627631

Group type: EXPERIMENTAL
Intervention: Cilostazol (200 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (calcium tablet)
Number of subjects: 21
Study: 38627668

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone 0.15 mg/kg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no dexamethasone)
Number of subjects: 70
Study: 38627686

Group type: EXPERIMENTAL
Intervention: TapTalk smartphone test
Number of subjects: 1382
Study: 38627712

Group type: EXPERIMENTAL
Intervention: Smart Bioactive Trabecular Coating (SBTC®)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (commercial electrochemical surface treatment)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: SBTC®
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both groups (SBTC® and Control)
Number of subjects: 20
Study: 38627722

Group type: EXPERIMENTAL
Intervention: A. annua plus M. oleifera
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: A. annua
Number of subjects: 282

Group type: COMPARATOR
Intervention: Routine standard of care only
Number of subjects: 282
Study: 38627795

Group type: EXPERIMENTAL
Intervention: Antimicrobial stewardship intervention (including voluntary continuing medical education for primary care physicians, distribution of written guidelines, implementation of project homepage, onsite training for nursing staff)
Number of subjects: 326

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Antimicrobial stewardship intervention
Number of subjects: 326

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 326
Study: 38627799

Group type: EXPERIMENTAL
Intervention: SAIA-TB intervention
Number of subjects: 16
Study: 38627819

Group type: EXPERIMENTAL
Intervention: 3D-printed implant-retained mandibular overdentures (IMO)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Traditional denture manufacturing methods
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 3D-printed IMO
Number of subjects: 26
Study: 38627823

Group type: EXPERIMENTAL
Intervention: ECPR-based approach (intra-arrest transport, ECPR if ROSC is not achieved prehospital and immediate invasive assessment)
Number of subjects: 256

Group type: COMPARATOR
Intervention: CCPR (conventional CPR)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: ECPR-based approach
Number of subjects: 256

Group type: COMPARATOR
Intervention: CCPR
Number of subjects: 256
Study: 38627837

Group type: EXPERIMENTAL
Intervention: 30 sessions of individual schema therapy
Number of subjects: 129

Group type: COMPARATOR
Intervention: Treatment as usual (mainly group-based, short-term cognitive behaviour or psychodynamic therapy)
Number of subjects: 129
Study: 38627843

Group type: EXPERIMENTAL
Intervention: Parent-Child Assistance Program (PCAP)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Services as usual
Number of subjects: 200
Study: 38627850

Group type: EXPERIMENTAL
Intervention: Online compassion-based self-help intervention for depression (6 weeks with email support)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Online compassion-based self-help intervention for depression
Number of subjects: 34
Study: 38628080

Group type: EXPERIMENTAL
Intervention: Gender-focused HIV risk-reduction intervention
Number of subjects: 500

Group type: COMPARATOR
Intervention: HIV testing
Number of subjects: 500
Study: 38628260

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 43

Group type: COMPARATOR
Intervention: Group analyses
Number of subjects: 43
Study: 38628315

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl
Number of subjects: 38

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 38
Study: 38628555

Group type: EXPERIMENTAL
Intervention: Genetic group (bupropion or varenicline based on genetic markers)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Control group (varenicline treatment)
Number of subjects: 361
Study: 38628675

Group type: EXPERIMENTAL
Intervention: Various approaches to create an effective anti-HIV-1 vaccine
Number of subjects: 40100000

Group type: EXPERIMENTAL
Intervention: Immunogen presentation modalities
Number of subjects: 40100000
Study: 38629062

Group type: EXPERIMENTAL
Intervention: COVID-19 Ad5-nCoV adenovirus vaccine
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 69
Study: 38629273

Group type: EXPERIMENTAL
Intervention: LAA patency detected by cardiac computed tomography angiography at 3 months post-LAA closure
Number of subjects: 519

Group type: COMPARATOR
Intervention: Complete closure of LAA
Number of subjects: 519
Study: 38629286

Group type: EXPERIMENTAL
Intervention: Sinus Rhythm (SR)
Number of subjects: 1240

Group type: COMPARATOR
Intervention: No AF recorded during follow-up
Number of subjects: 1240
Study: 38629312

Group type: COMPARATOR
Intervention: Conservative strategy
Number of subjects: 2591
Study: 38629403

Group type: EXPERIMENTAL
Intervention: EMDR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Narrative Therapy
Number of subjects: 0
Study: 38629416

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 10872

Group type: COMPARATOR
Intervention: No LV recovery (control group)
Number of subjects: 10872

Group type: EXPERIMENTAL
Intervention: Patients with no previous myocardial infarction (MI) and mean aortic valve gradient (mAVG) >40 mmHg
Number of subjects: 10872

Group type: EXPERIMENTAL
Intervention: Patients with baseline LV function (EF) >30%
Number of subjects: 10872
Study: 38629420

Group type: EXPERIMENTAL
Intervention: Angiography-guided coronary revascularisation strategy
Number of subjects: 320

Group type: COMPARATOR
Intervention: Physiology-guided coronary revascularisation strategy
Number of subjects: 320
Study: 38629508

Group type: EXPERIMENTAL
Intervention: Plasma eligibility screening
Number of subjects: 4905

Group type: EXPERIMENTAL
Intervention: PET eligibility screening
Number of subjects: 4905
Study: 38629811

Group type: EXPERIMENTAL
Intervention: Ketamine (initial bolus 0.23 mg/kg, continuous infusion 0.58 mg/kg/hr)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 38630086

Group type: EXPERIMENTAL
Intervention: MR elastography liver stiffness measurement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38630186

Group type: EXPERIMENTAL
Intervention: Secondary furlow palatoplasty with buccal myomucosal flap (FPBF)
Number of subjects: 23
Study: 38630259

Group type: EXPERIMENTAL
Intervention: TAU plus mobile phone intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 120

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 120
Study: 38630297

Group type: EXPERIMENTAL
Intervention: Sutured AMIC
Number of subjects: 47

Group type: COMPARATOR
Intervention: MFx
Number of subjects: 47
Study: 38630372

Group type: EXPERIMENTAL
Intervention: Extensively-assisted weaning with spontaneous breathing trial (SBT) using pressure support (PS) and positive end-expiratory pressure (PEEP)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard weaning with SBT using T-piece (TP)
Number of subjects: 98
Study: 38630457

Group type: EXPERIMENTAL
Intervention: Erenumab 140 mg subcutaneously every 4 weeks for 12 weeks
Number of subjects: 30
Study: 38630471

Group type: EXPERIMENTAL
Intervention: Oral antibiotics monotherapy (moxifloxacin, 400 mg/d for 7 days)
Number of subjects: 582

Group type: COMPARATOR
Intervention: Combined IV and oral antibiotics (IV ertapenem 1 g/d for 2 days plus oral levofloxacin 500 mg/d and metronidazole 500 mg 3 times/d for 5 days)
Number of subjects: 582

Group type: COMPARATOR
Intervention: Comparison of treatment success rates
Number of subjects: 582

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 582
Study: 38630489

Group type: EXPERIMENTAL
Intervention: Clopidogrel plus placebo
Number of subjects: 7758

Group type: COMPARATOR
Intervention: Clopidogrel plus aspirin
Number of subjects: 7758
Study: 38630494

Group type: EXPERIMENTAL
Intervention: Atrial shunt device
Number of subjects: 621
Study: 38630524

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) and mindfulness meditation (MM) training
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of intravenous ketamine and CBT/MM
Number of subjects: 30
Study: 38630525

Group type: EXPERIMENTAL
Intervention: Traditional facemask preoxygenation using normal breathing
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Humidified high-flow nasal oxygen, closed-mouth breathing, at 50 l min -1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Standard nasal cannula, closed-mouth breathing, at 50 l min -1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard nasal cannula
Number of subjects: 20
Study: 38630551

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks
Number of subjects: 72
Study: 38630781

Group type: EXPERIMENTAL
Intervention: FAP-IL2v (fibroblast activation protein α-targeted IL2 variant) administered intravenously once weekly, starting dose 5 mg, with dose escalation up to 25 mg and various uptitration regimens.
Number of subjects: 61
Study: 38630908

Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin (2.5 mg/kg) plus pembrolizumab (200 mg)
Number of subjects: 34
Study: 38630948

Group type: EXPERIMENTAL
Intervention: High-efficacy disease-modifying treatments (H-DMT, n = 13)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Lower-efficacy treatment
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: High-efficacy disease-modifying treatments (H-DMT)
Number of subjects: 22
Study: 38630960

Group type: EXPERIMENTAL
Intervention: Migraine participants
Number of subjects: 296

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 296
Study: 38631003

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg every 3 weeks for up to 17 cycles)
Number of subjects: 994

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 994

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 994
Study: 38631243

Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment and exercise three times/week
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 150
Study: 38631504

Group type: EXPERIMENTAL
Intervention: In vitro fertilization treatment among patients undergoing UTx; 72 autologous single embryo transfers (ETs) occurred in 23 patients who completed at least one ET.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: First embryo transfer (ET) after IVF treatment cycle.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Second embryo transfer (ET) after IVF treatment cycle.
Number of subjects: 31

Group type: COMPARATOR
Intervention: Programmed protocols for endometrial preparation (n = 61) vs. natural cycle protocols (n = 9).
Number of subjects: 31

Group type: COMPARATOR
Intervention: Living donor uteri vs. deceased donor uteri.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Posttransplant ovarian stimulation.
Number of subjects: 31
Study: 38631679

Group type: EXPERIMENTAL
Intervention: AI-MST and targeted doctor's guidance by remote micromessaging
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard-of-care oral hygiene regimen
Number of subjects: 100
Study: 38631712

Group type: EXPERIMENTAL
Intervention: CNCT19 (anti-CD19 CAR T-cell) after myeloablative high-dose chemotherapy and autologous stem cell transplantation (HDT/ASCT)
Number of subjects: 25
Study: 38631764

Group type: EXPERIMENTAL
Intervention: Losmapimod (15 mg twice a day)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Losmapimod
Number of subjects: 80
Study: 38631826

Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg daily
Number of subjects: 66000

Group type: EXPERIMENTAL
Intervention: Aspirin 150 mg daily
Number of subjects: 66000

Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg with metformin 1.5 g daily
Number of subjects: 66000
Study: 38631829

Group type: EXPERIMENTAL
Intervention: Non-operative management (NOM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Operative management
Number of subjects: 0
Study: 38631833

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) - exercise sessions consist of alternating brief high-intensity (≥85% of the peak heart rate) for 12 weeks, three times a week.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Moderate-Intensity Exercise (MOD) - exercise sessions for 12 weeks, three times a week.
Number of subjects: 60
Study: 38631835

Group type: EXPERIMENTAL
Intervention: Stimulant
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Stimulant and Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: N-of-1 trials
Number of subjects: 20
Study: 38631840

Group type: EXPERIMENTAL
Intervention: Non-reflective decision assistance strategy based on reminders and decision support tools
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decision information strategy based on knowledge dissemination and reflective decision structure strategy through audit/feedback
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (non-reflective decision assistance strategy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All strategies
Number of subjects: 0
Study: 38631841

Group type: EXPERIMENTAL
Intervention: Restrictive use of physical restraints (PR)
Number of subjects: 422

Group type: COMPARATOR
Intervention: Systematic use of physical restraints (PR)
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Both groups (Restrictive and Systematic PR)
Number of subjects: 422
Study: 38631936

Group type: EXPERIMENTAL
Intervention: Comprehensive invasive coronary functional testing
Number of subjects: 0
Study: 38632115

Group type: EXPERIMENTAL
Intervention: 12-week resistance-exercise intervention supervised by real-time videoconference
Number of subjects: 130
Study: 38632117

Group type: EXPERIMENTAL
Intervention: Non-operative treatment (antibiotics alone or in combination with percutaneous drainage)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: CT scan Hinchey classification IIb
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Tobacco smoking
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Presence of air bubbles inside the abscess
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Percutaneous drainage in patients with abscesses > 5 cm
Number of subjects: 116
Study: 38632179

Group type: EXPERIMENTAL
Intervention: REP+CONNECT
Number of subjects: 8

Group type: COMPARATOR
Intervention: REP-only
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: STRIDE program participation
Number of subjects: 8
Study: 38632262

Group type: EXPERIMENTAL
Intervention: Bovine colostrum (n = 25)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: N-acetyl glucosamine (n = 24)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Subcutaneous teduglutide (n = 26)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Budesonide (n = 25)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Standard care only (n = 25)
Number of subjects: 125
Study: 38632279

Group type: EXPERIMENTAL
Intervention: Maternal inflammation and cytomegalovirus viraemia
Number of subjects: 0
Study: 38632457

Group type: EXPERIMENTAL
Intervention: SPH3127 50 mg
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: SPH3127 100 mg
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: SPH3127 200 mg
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 38632501

Group type: EXPERIMENTAL
Intervention: EGCG nebulization 10 ml three times daily for at least seven days, with dose escalation from 1760 umol/L to 8817 umol/L.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: EGCG nebulization at 8817 umol/L.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: EGCG nebulization treatment.
Number of subjects: 60
Study: 38632556

Group type: EXPERIMENTAL
Intervention: Home-based exercise training intervention
Number of subjects: 146

Group type: COMPARATOR
Intervention: Attention control (i.e., stretching)
Number of subjects: 146
Study: 38632602

Group type: EXPERIMENTAL
Intervention: Laparoscopic approach for emergency colorectal surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open approach for emergency colorectal surgery
Number of subjects: 0
Study: 38632603

Group type: EXPERIMENTAL
Intervention: GC-PLUS (full version of Get Connected WebApp)
Number of subjects: 0

Group type: COMPARATOR
Intervention: GC-TLO (attention-control version of Get Connected WebApp)
Number of subjects: 0
Study: 38632647

Group type: EXPERIMENTAL
Intervention: Active theta-burst stimulation (TBS) to the left dorsolateral prefrontal cortex (DLPFC) and the vermis of the cerebellum, 1800 stimuli daily for 4 weeks.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham stimulation.
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Active theta-burst stimulation (TBS).
Number of subjects: 90
Study: 38632661

Group type: EXPERIMENTAL
Intervention: Extracorporeal Cardiopulmonary Resuscitation (ECPR) initiated by Helicopter Emergency Medical Services System (HEMS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group: Treatment by ambulance crew and HEMS without prehospital ECPR capabilities
Number of subjects: 0
Study: 38632826

Group type: EXPERIMENTAL
Intervention: Tezepelumab 210 mg subcutaneously every 4 weeks (Q4W)
Number of subjects: 1368

Group type: EXPERIMENTAL
Intervention: Tezepelumab 210 mg subcutaneously Q4W
Number of subjects: 1368
Study: 38632892

Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment (OMT)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Light touch (control)
Number of subjects: 38
Study: 38632977

Group type: EXPERIMENTAL
Intervention: risankizumab
Number of subjects: 0
Study: 38633575

Group type: EXPERIMENTAL
Intervention: Frontline systemic therapy at diagnosis or after observation
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: MZL-IPI (new prognostic score)
Number of subjects: 501
Study: 38633754

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 21

Group type: COMPARATOR
Intervention: Obesity (baseline)
Number of subjects: 21
Study: 38633771

Group type: EXPERIMENTAL
Intervention: Transcutaneous auricular vagus nerve stimulation (taVNS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 24
Study: 38633772

Group type: EXPERIMENTAL
Intervention: Behavioral economics-informed intervention bundle including default scheduling of postpartum PCP appointments and tailored messages.
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 360
Study: 38633812

Group type: EXPERIMENTAL
Intervention: Transport reimbursement (R)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Intensified health education (IHE)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: SMS/Telephone tracing (Te)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: RITe intervention (combined R, IHE, Te)
Number of subjects: 300
Study: 38634282

Group type: EXPERIMENTAL
Intervention: EHR alert with individualized LLT recommendations
Number of subjects: 2500

Group type: COMPARATOR
Intervention: No alert
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: EHR alert (among patients whose clinicians did not dismiss the alert)
Number of subjects: 2500

Group type: COMPARATOR
Intervention: No alert (among patients whose clinicians did not dismiss the alert)
Number of subjects: 2500
Study: 38634292

Group type: EXPERIMENTAL
Intervention: Stage II hypertension
Number of subjects: 204

Group type: COMPARATOR
Intervention: Normal blood pressure (BP)
Number of subjects: 204
Study: 38634481

Group type: EXPERIMENTAL
Intervention: BlueWind Implantable Tibial Neuromodulation (iTNM) system
Number of subjects: 151
Study: 38634928

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (second-line therapy)
Number of subjects: 836
Study: 38635026

Group type: EXPERIMENTAL
Intervention: Healthful Plant-Based Diet Index (hPDI)
Number of subjects: 64655

Group type: EXPERIMENTAL
Intervention: Unhealthful Plant-Based Diet Index (uPDI)
Number of subjects: 64655

Group type: EXPERIMENTAL
Intervention: Overall Plant-Based Diet Index (PDI)
Number of subjects: 64655

Group type: EXPERIMENTAL
Intervention: Higher hPDI scores
Number of subjects: 64655
Study: 38635060

Group type: EXPERIMENTAL
Intervention: Dependent care theory-based post-surgical home care intervention
Number of subjects: 0
Study: 38635115

Group type: EXPERIMENTAL
Intervention: Medication review with follow-up (intervention group)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 27
Study: 38635133

Group type: EXPERIMENTAL
Intervention: fNIRS intervention during verbal fluency test
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: fNIRS intervention during emotion recall task
Number of subjects: 62

Group type: COMPARATOR
Intervention: fNIRS intervention
Number of subjects: 62
Study: 38635151

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (M-Body)
Number of subjects: 45
Study: 38635190

Group type: EXPERIMENTAL
Intervention: Personalized Depression Prevention program
Number of subjects: 204

Group type: COMPARATOR
Intervention: Another evidence-based youth depression prevention program
Number of subjects: 204